Traders Recap: FreeSeas, Smithfield Foods, Angie's List, Horizon Pharma

Lakeway, TX -- (SBWIRE) -- 03/07/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

FreeSeas Inc. (NASDAQ:FREE) shares jumped 19.35% to $1.85. The company, on Feb. 14, announced that the Company's Amended and Restated Articles of Incorporation were amended to effect a reverse stock split of the Company's issued and outstanding common stock at a ratio of one new share for every 10 shares currently outstanding.

How Should Investors Trade FREE After The Recent Movement? Find Out Here

Smithfield Foods, Inc. (NYSE:SFD) shares climbed 10.40% to $24.62 after the company today reported strong fiscal 2013 third quarter results, driven by growth in packaged meats and solid contributions from international operations, as the company continued to execute its plan to transform into a more value-added consumer packaged meats company. Sales for the third quarter of fiscal 2013 were $3.6 billion, up 3%, resulting from higher volumes in all segments. Net income was $81.5 million ($.58 per diluted share) compared to net income of $79.0 million ($.49 per diluted share) last year. After adjusting for Campofrio and early debt extinguishment charges, adjusted EPS in the third quarter of fiscal 2012 was $.69 on a non-GAAP basis.

Is SFD Strong Buy After The Recent Strong Gains? Get Free Trend Analysis Here

Angie's List Inc (NASDAQ:ANGI) shares jumped 6.25% to $19.38. Equities research analysts at Piper Jaffray started coverage on shares of ANGI in a research note issued to investors yesterday. The firm set an “overweight” rating and a $25.00 price target on the stock.

Additionally, the company, on Feb. 13, announced that for first quarter of 2013, it expects revenue to be in the range of $51.0 million to $52.0 million. Analysts are expecting the Company to report revenue of $50 million for first quarter of 2013.

Is ANGI a Buying Opportunity After The Recent Plunge? Don’t Miss Out Our Latest Report Here

Horizon Pharma Inc (NASDAQ:HZNP) shares climbed 10.24% to $2.05 after the company today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for DUEXIS® (ibuprofen/famotidine) for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who require regular treatment with high dose ibuprofen administered three times a day and who are at risk of developing non-steroidal anti-inflammatory drug (NSAID) associated gastric and/or duodenal ulcers

How Should Investors Trade HZNP After The Latest Earnings Report? Find Out Here

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.